Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2018-05-23 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
发行股份购买资产并募集配套资金暨关联交易报告书（草案）（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed report titled "重大资产重组报告书（草案）（修订稿）" which translates to "Major Asset Restructuring Report (Draft) (Revised)". It discusses the issuance of shares to purchase assets and the raising of supporting funds, including detailed transaction parties, pricing, share issuance, lock-up arrangements, profit forecasts, compensation arrangements, and risk disclosures. It references regulatory approvals needed from the China Securities Regulatory Commission (CSRC) and the Shanghai Stock Exchange, and includes financial impact analysis and shareholder structure changes. The document is lengthy (15,000 characters) and contains substantive financial and transactional data, not merely an announcement or summary. It is a comprehensive disclosure related to a major asset restructuring transaction involving issuance of shares and capital raising, which fits the category of Capital/Financing Update (CAP). It is not an Annual Report, Audit Report, or Earnings Release, nor is it a simple announcement or proxy material. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2018-05-23 Chinese
关于《中国证监会行政许可项目审查一次反馈意见通知书》之反馈意见回复公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. regarding their response to a feedback notice from the China Securities Regulatory Commission (CSRC) related to an administrative licensing project review. It mentions the company's submission of materials and the uncertainty regarding approval of a major asset restructuring plan. The document is short (616 characters) and serves as a disclosure or regulatory update rather than a full report or detailed financial document. It does not contain financial statements, earnings data, or detailed management discussion. It is an official regulatory announcement related to compliance and administrative review, fitting best under Regulatory Filings (RNS).
2018-05-23 Chinese
瑞华会计师事务所（特殊普通合伙）关于上海傲源医疗用品有限公司业绩真实性的专项核查报告
Audit Report / Information Classification · 100% confidence The document is a detailed audit report by Ruihua Certified Public Accountants on the financial performance and authenticity of Shanghai Aoyuan Medical Supplies Co., Ltd. for the years 2015, 2016, and 2017. It includes extensive financial data, audit procedures, verification of revenues, costs, related party transactions, and internal controls. The document is addressed to the China Securities Regulatory Commission and relates to the financial audit work for a transaction involving asset acquisition and fundraising. The presence of detailed audit findings, financial data, and audit conclusions indicates this is a standalone audit report rather than a full annual report or other filing. It is not a brief announcement or certification letter but a comprehensive audit verification document. Therefore, the appropriate classification is Audit Report / Information (AR). FY 2017
2018-05-23 Chinese
关于发行股份购买资产并募集配套资金暨关联交易报告书（草案）修订说明的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company regarding revisions and supplementary disclosures to a previously issued report titled '发行股份购买资产并募集配套资金暨关联交易报告书（草案）' (Draft Report on Issuance of Shares to Purchase Assets and Raise Supporting Funds and Related Party Transactions). The text references multiple chapters and sections of this report, indicating it is a supplement or amendment to a comprehensive transaction report. The content includes detailed financial, asset, and transaction disclosures, as well as compliance with regulatory feedback from the China Securities Regulatory Commission. The document is not the report itself but an announcement explaining revisions and additional disclosures to the report. The length is about 5969 characters, which is moderate but the content is focused on describing changes to a report rather than presenting full financial statements or analysis. Therefore, this document fits best as a Regulatory Filing (RNS) because it is an official regulatory announcement about amendments to a transaction report, not the full report itself or a simple publication announcement. Confidence is high due to the detailed nature and regulatory context.
2018-05-23 Chinese
东兴证券股份有限公司关于《中源协和细胞基因工程股份有限公司关于＜中国证监会行政许可项目审查一次反馈意见通知书＞（180232号）之反馈意见回复》之专项核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed response from Dongxing Securities, acting as an independent financial advisor, addressing feedback from the China Securities Regulatory Commission (CSRC) regarding a major asset restructuring transaction involving Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. The content includes extensive supplementary disclosures, legal opinions, financial data, and compliance with regulatory disclosure standards related to a significant asset acquisition and related financing. The document references the '重组报告书' (Restructuring Report) and addresses multiple detailed issues about asset ownership, intellectual property, financial conditions, and regulatory approvals. This type of document is characteristic of a detailed regulatory response and supplementary information related to a major asset restructuring transaction, which aligns with the category of Capital/Financing Update (CAP) filings, as it involves updates on a significant financing and asset acquisition transaction. It is not a full annual or interim report, audit report, or earnings release, but a comprehensive update and response related to a capital transaction and associated regulatory feedback.
2018-05-23 Chinese
东兴证券股份有限公司关于上海傲源医疗用品有限公司业绩真实性的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" which translates to a "Special Verification Report" on the performance authenticity of Shanghai Aoyuan Medical Supplies Co., Ltd. It is prepared by an independent financial advisor for a transaction involving share issuance and asset purchase. The document contains detailed financial data for the years 2015, 2016, and 2017, including revenue, costs, profit, and detailed verification procedures such as contract reviews, customer and supplier confirmations, and internal control assessments. The document is a standalone audit or verification report focusing on the authenticity of financial performance for a specific transaction and period, rather than a full annual report or earnings release. It is not a regulatory announcement or a brief summary but a comprehensive audit-type report. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2017
2018-05-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.